ClinicalTrials.gg
CompletedNCT03589885MATUREUpdated Oct 11, 2021Results posted

Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis

A Phase 3 interventional study of Placebo 2 mL auto-injector and Placebo 1 mL prefilled syringe in Plaque Psoriasis, sponsored by Novartis Pharmaceuticals. Completed at 22 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-11.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
122
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing secukinumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. secukinumab · Psoriasis.

Enrollment
28th of 54
122 · median 124
Started
2018
with 1 other
Phase 3
24 of 54
none open now
Registered
41st of 54
by date
Lead sponsor
37 of 54
Novartis Pharmaceuticals

Among the 54 studies testing secukinumab in Psoriasis, this one is the 28th largest by enrollment, is one of 2 that started in 2018, is one of 24 in phase 3, and was the 41st registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 54 studies testing secukinumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About secukinumab

secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing secukinumab in Psoriasis, or all of them as a file.
02

Study summary

The primary purpose of this study is to assess efficacy, safety and tolerability of a 2 mL pre-filled auto-injector (AI) of 300 mg secukinumab in patients with moderate to severe plaque psoriasis

Read the detailed description

This is a 52-weeks multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in approximately 120 subjects with moderate to severe plaque-type psoriasis

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

Keywords

  • Plaque psoriasis, auto-injector, 2 mL injection, secukinumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects eligible for inclusion in this study must have fulfilled all of the following criteria:

  1. Men or Women of at least 18 years of age at time of Screening
  2. Subjects able to understand and communicate with the investigator and comply with the requirements of the study and must have given a written, signed and dated before any study related activity was performed. Where relevant, a legal representative signed the informed study consent according to local laws and regulations.
  3. Chronic plaque-type psoriasis present for at least 6 months and diagnosed before Randomization.
  4. Moderate to severe psoriasis as defined at Randomization by:

    • PASI score of 12 or greater, and
    • IGA mod 2011 score of 3 or greater (based on a scale of 0 - 4), and
    • Body Surface Area (BSA) affected by plaque-type psoriasis of 10% or greater.
  5. Candidate for systemic therapy. This is defined as a subject having moderate to severe chronic plaque-type psoriasis that is inadequately controlled by

    • Topical treatment and/or
    • Phototherapy and/or
    • Previous systemic therapy

Exclusion criteria

Exclusion Criteria:

  1. Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and guttate psoriasis) at Screening or Randomization.
  2. Ongoing use of prohibited treatments. detailed in the protocol had to be adhered to. Subjects not willing to limit UV light exposure (e.g., sunbathing and/or the use of tanning devices) during the course of the study were considered not eligible for this study since UV light exposure was prohibited.

    Note: administration of 6 weeks prior to Randomization or during the study period was also prohibited.

  3. Previous exposure to secukinumab (AIN457) or any other biologic drug directly targeting IL-17 or the IL-17 receptor.
  4. Use of other drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 30 days until the expected pharmacodynamic effect had returned to baseline, whichever is longer; or longer if required by local regulations.
  5. Pregnant or nursing (lactating) women, where pregnancy was defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.
  6. History of lymphoproliferative disease or any known or history of malignancy of any organ system treated or untreated within the past 5 years, regardless of whether there was evidence of local recurrence or (except for Bowen's disease, or basal cell carcinoma or actinic keratoses that had been treated with no evidence of recurrence in the past 12 weeks; carcinoma in situ of the cervix or non-invasive malignant colon polyps that have been removed).
  7. History of to any of study drug constituent
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
122 participants (actual)

Study arms

  • Placebo comparator
    Placebo 2 mL auto-injector

    Placebo to secukinumab s.c., provided in 2 mL auto-injector form

    Drug: Placebo 2 mL auto-injector

  • Placebo comparator
    Placebo 1 mL prefilled syringe

    Placebo to secukinumab s.c., provided in 2 \* 1 ml prefilled syringe form

    Drug: Placebo 1 mL prefilled syringe

  • Experimental
    Secukinumab 2 mL auto-injector

    Secukinumab 300 mg provided in 2 mL auto-injector form

    Drug: Secukinumab 2 mL auto-injector

  • Active comparator
    Secukinumab 1 mL prefilled syringe

    Secukinumab 300 mg provided as 2x 1 mL prefilled syringe of 150 mg/mL

    Drug: Secukinumab 1 mL prefilled syringe

Interventions

  • DrugPlacebo 2 mL auto-injector

    All Placebo patients until week 8 (included): 2 mL auto-injector Placebo + 2x 1 mL prefilled syringe Placebo s.c. at randomization, weeks 1, 2, 3, 4 and 8. PASI 90 responders at week 12: 2 mL auto-injector placebo + 2x 1 mL prefilled syringe Placebo s.c. at weeks 12, 13, 14, 15, 16 and every 4 weeks thereafter until week 48. PASI 90 non-responders at week 12: 2 mL secukinumab 300 mg auto-injector + 2x 1 mL prefilled syringe Placebo s.c. at weeks 12, 13, 14, 15, 16 and 4-weekly thereafter until week 48

    Also known as: Placebo

  • DrugPlacebo 1 mL prefilled syringe

    All Placebo patients until week 8 (included): 2 mL auto-injector Placebo + 2x 1 mL prefilled syringe Placebo s.c. at randomization, weeks 1, 2, 3, 4 and 8. PASI 90 responders at week 12: 2 mL auto-injector Placebo + 2x 1 mL prefilled syringe Placebo s.c. at weeks 12, 13, 14, 15, 16 and every 4 weeks thereafter until week 48. PASI 90 non-responders at week 12: 2x 1 mL secukinumab 150 mg prefilled syringe + 2 mL auto-injector Placebo s.c. at weeks 12, 13, 14, 15, 16 and 4-weekly thereafter until week 48

    Also known as: Placebo

  • 2 mL secukinumab 300 mg auto-injector + 2x 1 mL prefilled syringe Placebo s.c. at randomization, weeks 1, 2, 3, 4, 8, 12, 13, 14, 15 , 16 and 4-weekly thereafter until week 48

  • 2 x 1 mL secukinumab 150 mg prefilled syringe + 2 mL auto-injector Placebo s.c. at randomization, weeks 1, 2, 3, 4, 8, 12, 13, 14, 15, 16 and 4-weekly thereafter until week 48

06

What researchers measure

Primary outcomes

  1. PASI 75 Response After 12 Weeks of Treatment

    Percentage of participants who achieve ≥ 75% reduction in PASI compared to baseline. A PASI (Psoriasis Area and Severity Index) score is a tool used to measure the severity and extent of psoriasis. The score ranges from 0 (no signs of psoriasis) to a theoretic maximum of 72. The intensity of redness, thickness and scaling of the psoriasis is assessed as none (0), mild (1), moderate (2), severe (3) or very severe (4).

    Time frame: 12 weeks

  2. IGA Mod 2011 0 or 1 Response After 12 Weeks of Treatment

    Percentage of participants who achieve IGA mod 2011 0 or 1, and improved by at least 2 points on the IGA scale compared to baseline. This scale ranges from 0 (clear, no signs of psoriasis) to 4 (severe).

    Time frame: 12 weeks

Secondary outcomes

  1. PASI 90 Response

    Percentage of participants who achieve ≥ 90% reduction in PASI compared to baseline

    Time frame: 12 weeks

  2. PASI 50, 75, 90 and 100 and IGA Mod 2011 0 or 1 Response

    Percentage of participants who achieve ≥ 50%, 75%, 90% and 100% reduction in PASI and achieve IGA mod 2011 0 or 1, and improved by at least 2 points on the IGA scale compared to baseline at each visit up to 52 weeks

    Time frame: 52 weeks

  3. Successful Self-injection

    Subject usability (ability to follow instructions for use and potential use-related hazards) and satisfaction with the new secukinumab 2 mL AI utilizing a self-administered Self-Injection Assessment Questionnaire (SIAQ) and investigator/site staff observation of secukinumab 300 mg 2 mL AI administration. The Satisfaction with Self-Injection (SA) domain score ranges from 0 (worst experience) to 10 (best experience).

    Time frame: From randomization until Week 28

  4. Dermatology Life Quality Index, (DLQI) 0 or 1 Score (Total Score)

    DLQI is a simple, compact, and practical questionnaire for use in a dermatology clinical setting to assess limitations related to the impact of skin disease. The instrument contains ten items dealing with the participant's skin. With the exception of Item Number 7, the participant responds on a four-point scale, ranging from "Very Much" (score 3) to "Not at All" or "Not relevant" (score 0). Item Number 7 is a multi-part item, the first part of which ascertains whether the participant's skin prevented them from working or studying (Yes or No, scores 3 or 0 respectively), and if "No," then the participant is asked how much of a problem the skin has been at work or study over the past week, with response alternatives being "A lot," "A little," or "Not at all" (scores 2, 1, or 0 respectively). The DLQI total score is derived by summing all item scores, which has a possible range of 0 to 30, with 30 corresponding to the worst quality of life, and 0 corresponding to the best.

    Time frame: Change from Baseline up to 52 weeks

07

Results

Posted Aug 26, 2021

Participant flow

A total of 144 subjects were screened at 22 study centers in 6 countries, and 122 subjects were randomized.

Treatment Period 1-Randomized Set
Participant flow — Treatment Period 1-Randomized Set
MilestoneSecukinumab 300 mg (2 mL AI)Secukinumab 300 mg (2x 1 mL PFS)PlaceboPlacebo-Secukinumab 300 mg (2 mL AI)Placebo-Secukinumab 300 mg (2 x 1 mL PFS)
Started41414000
Completed41393700
Not completed02300
Withdrew: Adverse event01000
Withdrew: Lack of efficacy00200
Withdrew: Lost to follow-up01000
Withdrew: Withdrawal by subject00100
Treatment Period 2-Randomized Set
Participant flow — Treatment Period 2-Randomized Set
MilestoneSecukinumab 300 mg (2 mL AI)Secukinumab 300 mg (2x 1 mL PFS)PlaceboPlacebo-Secukinumab 300 mg (2 mL AI)Placebo-Secukinumab 300 mg (2 x 1 mL PFS)
Started413941617
Completed403431616
Not completed15101
Withdrew: Adverse event01000
Withdrew: Pregnancy10000
Withdrew: Lost to follow-up03101
Withdrew: Withdrawal by subject01000

Outcome measures

PrimaryPASI 75 Response After 12 Weeks of Treatment

Percentage of participants who achieve ≥ 75% reduction in PASI compared to baseline. A PASI (Psoriasis Area and Severity Index) score is a tool used to measure the severity and extent of psoriasis. The score ranges from 0 (no signs of psoriasis) to a theoretic maximum of 72. The intensity of redness, thickness and scaling of the psoriasis is assessed as none (0), mild (1), moderate (2), severe (3) or very severe (4).

Time frame:
12 weeks
Reported as:
Number · Participants
PASI 75 Response After 12 Weeks of Treatment
ParticipantsSecukinumab 2 mL Auto-injectorSecukinumab 1 mL Prefilled SyringePlacebo
PASI 75 Response After 12 Weeks of Treatment39344
Statistical analysis
  • Secukinumab 2 mL Auto-injector vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 1014.07 · 95% CI 68.83 to 14940.62
  • Secukinumab 1 mL Prefilled Syringe vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 96.23 · 95% CI 17.22 to 537.78
PrimaryIGA Mod 2011 0 or 1 Response After 12 Weeks of Treatment

Percentage of participants who achieve IGA mod 2011 0 or 1, and improved by at least 2 points on the IGA scale compared to baseline. This scale ranges from 0 (clear, no signs of psoriasis) to 4 (severe).

Time frame:
12 weeks
Reported as:
Number · Participants
IGA Mod 2011 0 or 1 Response After 12 Weeks of Treatment
ParticipantsSecukinumab 2 mL Auto-injectorSecukinumab 1 mL Prefilled SyringePlacebo
IGA Mod 2011 0 or 1 Response After 12 Weeks of Treatment31283
Statistical analysis
  • Secukinumab 2 mL Auto-injector vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 51.46 · 95% CI 11.95 to 221.64
  • Secukinumab 1 mL Prefilled Syringe vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 29.70 · 95% CI 7.38 to 119.57
SecondaryPASI 90 Response

Percentage of participants who achieve ≥ 90% reduction in PASI compared to baseline

Time frame:
12 weeks
Reported as:
Number · Participants
PASI 90 Response
ParticipantsSecukinumab 2 mL Auto-injectorSecukinumab 1 mL Prefilled SyringePlacebo
PASI 90 Response31262
Statistical analysis
  • Secukinumab 2 mL Auto-injector vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 88.46 · 95% CI 16.15 to 484.52
  • Secukinumab 1 mL Prefilled Syringe vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 37.90 · 95% CI 7.60 to 189.01
SecondaryPASI 50, 75, 90 and 100 and IGA Mod 2011 0 or 1 Response

Percentage of participants who achieve ≥ 50%, 75%, 90% and 100% reduction in PASI and achieve IGA mod 2011 0 or 1, and improved by at least 2 points on the IGA scale compared to baseline at each visit up to 52 weeks

Time frame:
52 weeks
Reported as:
Number · Participants
PASI 50, 75, 90 and 100 and IGA Mod 2011 0 or 1 Response
ParticipantsSecukinumab 2 mL Auto-injectorSecukinumab 1 mL Prefilled SyringePlaceboPlacebo-Secukinumab 300 mg (2 mL Auto-injector)Placebo-Secukinumab 300 mg (2x 1 mL Prefilled Syringe)
PASI 50414041515
PASI 75383711314
PASI 90302801214
PASI 100231801111
IGA 0/1303301213
SecondarySuccessful Self-injection

Subject usability (ability to follow instructions for use and potential use-related hazards) and satisfaction with the new secukinumab 2 mL AI utilizing a self-administered Self-Injection Assessment Questionnaire (SIAQ) and investigator/site staff observation of secukinumab 300 mg 2 mL AI administration. The Satisfaction with Self-Injection (SA) domain score ranges from 0 (worst experience) to 10 (best experience).

Time frame:
From randomization until Week 28
Reported as:
Mean · Scores on a scale
Successful Self-injection
Scores on a scalePRE- Module by VisitPOST-module by VisitAbsolute Change POST Module -PRE Module
Baseline5.75 ± 2.442——
Baseline (1) =POST-module at baseline visit5.75 ± 2.4527.52 ± 2.0461.77 ± 2.789
Week 15.72 ± 2.4638.11 ± 1.7592.39 ± 3.169
Week 45.70 ± 2.4958.27 ± 1.7312.57 ± 3.080
Week 85.68 ± 2.4908.62 ± 1.5452.94 ± 2.869
Week 125.70 ± 2.5238.56 ± 1.6232.86 ± 2.985
Week 285.62 ± 2.4858.69 ± 1.6813.07 ± 3.238
SecondaryDermatology Life Quality Index, (DLQI) 0 or 1 Score (Total Score)

DLQI is a simple, compact, and practical questionnaire for use in a dermatology clinical setting to assess limitations related to the impact of skin disease. The instrument contains ten items dealing with the participant's skin. With the exception of Item Number 7, the participant responds on a four-point scale, ranging from "Very Much" (score 3) to "Not at All" or "Not relevant" (score 0). Item Number 7 is a multi-part item, the first part of which ascertains whether the participant's skin prevented them from working or studying (Yes or No, scores 3 or 0 respectively), and if "No," then the participant is asked how much of a problem the skin has been at work or study over the past week, with response alternatives being "A lot," "A little," or "Not at all" (scores 2, 1, or 0 respectively). The DLQI total score is derived by summing all item scores, which has a possible range of 0 to 30, with 30 corresponding to the worst quality of life, and 0 corresponding to the best.

Time frame:
Change from Baseline up to 52 weeks
Reported as:
Mean · Scores on a Scale
Dermatology Life Quality Index, (DLQI) 0 or 1 Score (Total Score)
Scores on a ScaleSecukinumab 2 mL Auto-injectorSecukinumab 1 mL Prefilled SyringePlacebo
Week 12-13.21 ± 7.701-11.95 ± 7.861-1.97 ± 6.966
Week 28-13.59 ± 7.639-12.23 ± 8.438-13.00 ± 12.490
Week 52-12.44 ± 8.219-12.23 ± 8.408-14.33 ± 11.240

Adverse events

Collected over Adverse events were collected from first dose of study treatment until end of study treatment (Week 48) plus 4 weeks post treatment.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Secukinumab 300 mg (2 mL Auto-Injector)0/41 (0%)1/41 (2.4%)19/41 (46.3%)
Secukinumab 300 mg (2 x 1 mL PFS)0/41 (0%)3/41 (7.3%)16/41 (39%)
Any Secukinumab 300 mg (2 mL AI)0/57 (0%)1/57 (1.8%)24/57 (42.1%)
Any Secukinumab 300 mg (2 x 1 mL PFS)0/58 (0%)4/58 (6.9%)21/58 (36.2%)
Placebo0/40 (0%)0/40 (0%)5/40 (12.5%)
Any Secukinumab 300 mg0/115 (0%)5/115 (4.3%)45/115 (39.1%)
Most frequent serious events
Most frequent serious events
EventSecukinumab 300 mg (2 mL Auto-Injector)Secukinumab 300 mg (2 x 1 mL PFS)Any Secukinumab 300 mg (2 mL AI)Any Secukinumab 300 mg (2 x 1 mL PFS)PlaceboAny Secukinumab 300 mg
AppendicitisInfections and infestations0/411/410/571/580/401/115
COVID-19Infections and infestations0/411/410/571/580/401/115
Device related infectionInfections and infestations1/410/411/570/580/401/115
ConcussionInjury, poisoning and procedural complications0/411/410/571/580/401/115
Head injuryInjury, poisoning and procedural complications0/411/410/571/580/401/115
Road traffic accidentInjury, poisoning and procedural complications0/411/410/571/580/401/115
SyncopeNervous system disorders0/411/410/571/580/401/115
AsthmaRespiratory, thoracic and mediastinal disorders0/410/410/571/580/401/115
Most frequent other events
Most frequent other events
EventSecukinumab 300 mg (2 mL Auto-Injector)Secukinumab 300 mg (2 x 1 mL PFS)Any Secukinumab 300 mg (2 mL AI)Any Secukinumab 300 mg (2 x 1 mL PFS)PlaceboAny Secukinumab 300 mg
NasopharyngitisInfections and infestations6/416/418/578/580/4016/115
Upper respiratory tract infectionInfections and infestations3/414/414/576/581/4010/115
HeadacheNervous system disorders2/414/413/574/581/407/115
HypertensionVascular disorders4/412/415/572/580/407/115
NauseaGastrointestinal disorders0/413/410/573/580/403/115
Influenza like illnessGeneral disorders3/413/414/573/581/407/115
PruritusSkin and subcutaneous tissue disorders3/412/413/573/582/406/115

Baseline characteristics

Full Analysis set (FAS) consisted of 122 subjects and used for efficacy analyses.

Age, Customized
Age, Customized(Participants)Secukinumab 2 mL Auto-injectorSecukinumab 1 mL Prefilled SyringePlaceboTotal
< 65393736112
≥ 6524410
Sex: Female, Male
Sex: Female, Male(Participants)Secukinumab 2 mL Auto-injectorSecukinumab 1 mL Prefilled SyringePlaceboTotal
Female13121237
Male28292885
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Secukinumab 2 mL Auto-injectorSecukinumab 1 mL Prefilled SyringePlaceboTotal
American Indian or Alaska Native0101
Asian1135
Native Hawaiian or Other Pacific Islander0000
Black or African American1001
White393937115
More than one race0000
Unknown or Not Reported0000
08

Study locations

22 sites
  • Novartis Investigative Site
    Miami, Florida 33155, United States
  • Novartis Investigative Site
    Marietta, Georgia 30060, United States
  • Novartis Investigative Site
    Saint Joseph, Missouri 64506, United States
  • Novartis Investigative Site
    Verona, New Jersey 07044, United States
  • Novartis Investigative Site
    Portland, Oregon 97210, United States
  • Novartis Investigative Site
    Houston, Texas 77030, United States
  • Novartis Investigative Site
    San Antonio, Texas 78218, United States
  • Novartis Investigative Site
    Sugar Land, Texas 77479, United States
  • Novartis Investigative Site
    Edmonton, Alberta T5K 1X3, Canada
  • Novartis Investigative Site
    Surrey, British Columbia V3R 6A7, Canada
  • Novartis Investigative Site
    Bielefeld, 33647, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Vechta, 49377, Germany
  • Novartis Investigative Site
    Witten, 58453, Germany
  • Novartis Investigative Site
    Kopavogur, 201, Iceland
  • Novartis Investigative Site
    Warszawa, Mazowian 02 495, Poland
  • Novartis Investigative Site
    Wroclaw, 50-566, Poland
  • Novartis Investigative Site
    Alicante, Comunidad Valenciana 03010, Spain
  • Novartis Investigative Site
    Valencia, Comunidad Valenciana 46014, Spain
  • Novartis Investigative Site
    Barcelona, 08003, Spain
  • Novartis Investigative Site
    Madrid, 28031, Spain
  • Novartis Investigative Site
    Madrid, 28041, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Nov 2019, 11 months.

Results were first posted in Aug 2021, 1 year 9 months after primary completion. A results delay was requested in Feb 2020.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 11 months is below that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2018
First posted
Jul 18, 2018
StartActual
Dec 19, 2018
Primary completionActual
Nov 19, 2019
CompletionActual
Aug 5, 2020
Results delay requested
Feb 12, 2020
Results first posted
Aug 26, 2021
Last update
Oct 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03589885
Responsible party
Sponsor
First posted
Jul 18, 2018
Start date
Dec 19, 2018
Primary completion
Nov 19, 2019
Completion
Aug 5, 2020
Results posted
Aug 26, 2021
Last update
Oct 11, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion